Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Want to see DNTH full AI Analyst Report?
DNTH Stock Chart & Stats
$93.26
$0.37(1.44%)
At close: 4:00 PM EST
$93.26
$0.37(1.44%)
Day’s Range― - ―
52-Week Range$16.64 - $96.50
Previous CloseN/A
Volume29.07K
Average Volume (3M)1.00M
Market Cap
$4.62B
Enterprise Value$3.26B
Total Cash (Recent Filing)$1.11B
Total Debt (Recent Filing)$1.36M
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 06, 2026EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding54,666,233
10 Day Avg. Volume588,847
30 Day Avg. Volume1,003,841
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap0.70
Enterprise Value/Revenue2.44K
Enterprise Value/Gross Profit2.58K
Enterprise Value/Ebitda-17.38
Forecast
1Y Price Target
$127.33Price Target Upside36.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-3.68
Revenue Forecast (FY)$1.18M
Bulls Say, Bears Say
Bulls Say
Strong Cash Runway & LiquidityA pro forma cash position (~$1.2B) and recent equity financing materially extend runway, allowing Dianthus to fund multiple late-stage programs and parallel trials through 2028–2030. This durable liquidity reduces near-term financing pressure and supports execution of registrational studies and portfolio strategy.
Late-stage Clinical MomentumAn early GO decision in Phase 3 CAPTIVATE de-risks the development path for claseprubart, enabling a faster, more efficient registrational trajectory. This clinical momentum supports building a neuromuscular franchise, improving the odds of successful pivotal readouts and strengthening long-term commercial potential if trials confirm benefit.
Governance Continuity And OversightShareholder support for existing directors and the auditor signals continuity in leadership and confidence in financial controls. Stable governance and recognized audit oversight provide durable operational stability and lower execution risk during complex late-stage development and multi-year clinical programs.
Bears Say
Persistent Negative Cash FlowOperating and free cash flows remain consistently negative and cash burn rose materially, creating a structural funding need over time. Even with current liquidity, sustained negative cash generation means the company remains dependent on capital markets or partnerships if programs extend or costs rise.
Deepening Operating LossesWidening EBIT/EBITDA losses reflect elevated R&D and G&A as Dianthus advances late-stage programs. Persistent losses compress returns on equity and make long-term value contingent on clinical success and commercialization, increasing binary program risk and strategic sensitivity to trial outcomes.
No Recurring Product Revenue; Financing RelianceAs a clinical-stage biotech with no approved products, Dianthus relies on equity financings and external funding. This structural dependence increases dilution and strategic vulnerability if capital markets tighten or development timelines slip, limiting long-term autonomy absent product revenues.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $16.64 and its highest was $96.50 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $4.62B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 57 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on May 05, 2026. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$1.072 by $0.222.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -0.85.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 54,666,233 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.85 in its last earnings report, beating expectations of -$1.072. Following the earnings report the stock price went up 0.199%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$127.33 (36.54% Upside)
$127.33 (36.54% Upside)
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.18%
12-Months-Change
Fundamentals
Return on Equity
-1.78%
Trailing 12-Months
Asset Growth
257.70%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-phase biotechnology firm dedicated to conceiving, developing, and providing cutting-edge monoclonal antibody treatments. These therapies are intended for individuals grappling with serious autoimmune and inflammatory conditions. The company's pipeline includes DNTH103, an investigational drug presently undergoing Phase 1 clinical assessment in patients diagnosed with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was established in 2015 and operates from its headquarters in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$127.33
▲(36.54% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
0.13% Insiders
24.04% Mutual Funds
55.84% Other Institutional Investors
10.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---